07:02 EDT Supernus (SUPN) to acquire Sage Therapeutics (SAGE) for $8.50 per share in cash plus CVR
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus expands partnership with Jay Glazer in new content series
- Supernus Pharmaceuticals Faces Patent Challenges for Qelbree
- Supernus announces Paragraph IV ANDA filings for Qelbree
- Supernus partners with Busy Philipps for new campaign
- Supernus Pharmaceuticals’ Earnings Call: Growth Amid Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue